-
XW04 Central Vein
-
XW040 Open
-
XW0400 Brexanolone
-
XW0400 Spesolimab Monoclonal Antibody
-
XW0401 Daratumumab and Hyaluronidase-fihj
-
XW0401 Eladocagene exuparvovec
-
XW0402 Bromelain-enriched Proteolytic Enzyme
-
XW0402 Nerinitide
-
XW0403 Durvalumab Antineoplastic
-
XW0403 Maribavir Anti-infective
-
XW0404 Teclistamab Antineoplastic
-
XW0405 Mosunetuzumab Antineoplastic
-
XW0405 Narsoplimab Monoclonal Antibody
-
XW0406 Afamitresgene Autoleucel Immunotherapy
-
XW0406 Lefamulin Anti-infective
-
XW0406 Terlipressin
-
XW0407 Coagulation Factor Xa, Inactivated
-
XW0407 Tabelecleucel Immunotherapy
-
XW0407 Trilaciclib
-
XW0408 Lurbinectedin
-
XW0408 Mineral-based Topical Hemostatic Agent
-
XW0408 Treosulfan
-
XW0408 Uridine Triacetate
-
XW0409 Ceftolozane/Tazobactam Anti-infective
-
XW0409 Inebilizumab-cdon
-
XW0409 Satralizumab-mwge
-
XW040A Cefiderocol Anti-infective
-
XW040A Ciltacabtagene Autoleucel
-
XW040B Amivantamab Monoclonal Antibody
-
XW040B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW040B Omadacycline Anti-infective
-
XW040C Eculizumab
-
XW040C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW040D Atezolizumab Antineoplastic
-
XW040D Engineered Allogeneic Thymus Tissue
-
XW040E Etesevimab Monoclonal Antibody
-
XW040E Remdesivir Anti-infective
-
XW040F Bamlanivimab Monoclonal Antibody
-
XW040F Other New Technology Therapeutic Substance
-
XW040G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW040G Plazomicin Anti-infective
-
XW040G REGN-COV2 Monoclonal Antibody
-
XW040G Sarilumab
-
XW040H Axicabtagene Ciloleucel Immunotherapy
-
XW040H Other New Technology Monoclonal Antibody
-
XW040H Synthetic Human Angiotensin II
-
XW040H Tocilizumab
-
XW040J Apalutamide Antineoplastic
-
XW040J Tisagenlecleucel Immunotherapy
-
XW040K Fosfomycin Anti-infective
-
XW040K Idecabtagene Vicleucel Immunotherapy
-
XW040K Leronlimab Monoclonal Antibody
-
XW040L CD24Fc Immunomodulator
-
XW040L Erdafitinib Antineoplastic
-
XW040L Lifileucel Immunotherapy
-
XW040M Baricitinib
-
XW040M Brexucabtagene Autoleucel Immunotherapy
-
XW040M Esketamine Hydrochloride
-
XW040N Lisocabtagene Maraleucel Immunotherapy
-
XW040N Meropenem-vaborbactam Anti-infective
-
XW040P Antibiotic-eluting Bone Void Filler
-
XW040Q Tagraxofusp-erzs Antineoplastic
-
XW040R Fostamatinib
-
XW040R Venetoclax Antineoplastic
-
XW040S COVID-19 Vaccine Dose 1
-
XW040S Iobenguane I-131 Antineoplastic
-
XW040T COVID-19 Vaccine Dose 2
-
XW040T Ruxolitinib
-
XW040U COVID-19 Vaccine
-
XW040U Imipenem-cilastatin-relebactam Anti-infective
-
XW040V COVID-19 Vaccine Dose 3
-
XW040V Gilteritinib Antineoplastic
-
XW040W Caplacizumab
-
XW040W COVID-19 Vaccine Booster
-
XW040X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW040X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW040Y Other New Technology Monoclonal Antibody
-
-
XW043 Percutaneous
-
XW0430 Brexanolone
-
XW0430 Spesolimab Monoclonal Antibody
-
XW0431 Daratumumab and Hyaluronidase-fihj
-
XW0431 Eladocagene exuparvovec
-
XW0432 Bromelain-enriched Proteolytic Enzyme
-
XW04326Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0432 Nerinitide
-
XW04326Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0433 Durvalumab Antineoplastic
-
XW04336Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0433 Maribavir Anti-infective
-
XW04336Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0434 Teclistamab Antineoplastic
-
XW0435 Mosunetuzumab Antineoplastic
-
XW0435 Narsoplimab Monoclonal Antibody
-
XW0436 Afamitresgene Autoleucel Immunotherapy
-
XW04366Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0436 Lefamulin Anti-infective
-
XW04366Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0436 Terlipressin
-
XW04366Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0437 Coagulation Factor Xa, Inactivated
-
XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
-
XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0437 Tabelecleucel Immunotherapy
-
XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
-
XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0437 Trilaciclib
-
XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
-
XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0438 Lurbinectedin
-
XW0438 Mineral-based Topical Hemostatic Agent
-
XW0438 Treosulfan
-
XW0438 Uridine Triacetate
-
XW0439 Ceftolozane/Tazobactam Anti-infective
-
XW0439 Inebilizumab-cdon
-
XW0439 Satralizumab-mwge
-
XW043A Cefiderocol Anti-infective
-
XW043A Ciltacabtagene Autoleucel
-
XW043B Amivantamab Monoclonal Antibody
-
XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043B6Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043B6Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043B Omadacycline Anti-infective
-
XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043B6Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043C Eculizumab
-
XW043C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW043D Atezolizumab Antineoplastic
-
XW043D6Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW043D Engineered Allogeneic Thymus Tissue
-
XW043D6Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW043E Etesevimab Monoclonal Antibody
-
XW043E Remdesivir Anti-infective
-
XW043F Bamlanivimab Monoclonal Antibody
-
XW043F3Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043F5Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043F6Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW043F Other New Technology Therapeutic Substance
-
XW043F3Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043F5Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043F6Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
-
XW043G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW043G4Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043G Plazomicin Anti-infective
-
XW043G4Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043G REGN-COV2 Monoclonal Antibody
-
XW043G4Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043G Sarilumab
-
XW043G4Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043H Axicabtagene Ciloleucel Immunotherapy
-
XW043H4Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043H Other New Technology Monoclonal Antibody
-
XW043H4Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043H Synthetic Human Angiotensin II
-
XW043H4Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043H Tocilizumab
-
XW043H4Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
-
XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043J Apalutamide Antineoplastic
-
XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043J Tisagenlecleucel Immunotherapy
-
XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043K Fosfomycin Anti-infective
-
XW043K Idecabtagene Vicleucel Immunotherapy
-
XW043K Leronlimab Monoclonal Antibody
-
XW043L CD24Fc Immunomodulator
-
XW043L Erdafitinib Antineoplastic
-
XW043L Lifileucel Immunotherapy
-
XW043M Baricitinib
-
XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043M Brexucabtagene Autoleucel Immunotherapy
-
XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043M Esketamine Hydrochloride
-
XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
-
XW043N Lisocabtagene Maraleucel Immunotherapy
-
XW043N Meropenem-vaborbactam Anti-infective
-
XW043P Antibiotic-eluting Bone Void Filler
-
XW043Q Tagraxofusp-erzs Antineoplastic
-
XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043R Fostamatinib
-
XW043R Venetoclax Antineoplastic
-
XW043S COVID-19 Vaccine Dose 1
-
XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043S Iobenguane I-131 Antineoplastic
-
XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043T COVID-19 Vaccine Dose 2
-
XW043T Ruxolitinib
-
XW043U COVID-19 Vaccine
-
XW043U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043U Imipenem-cilastatin-relebactam Anti-infective
-
XW043U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043V COVID-19 Vaccine Dose 3
-
XW043V Gilteritinib Antineoplastic
-
XW043W Caplacizumab
-
XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043W COVID-19 Vaccine Booster
-
XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
-
XW043X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW043X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW043Y Other New Technology Monoclonal Antibody
-
-
XW047 Via Natural or Artificial Opening
-
XW0470 Brexanolone
-
XW0470 Spesolimab Monoclonal Antibody
-
XW0471 Daratumumab and Hyaluronidase-fihj
-
XW0471 Eladocagene exuparvovec
-
XW0472 Bromelain-enriched Proteolytic Enzyme
-
XW0472 Nerinitide
-
XW0473 Durvalumab Antineoplastic
-
XW0473 Maribavir Anti-infective
-
XW0474 Teclistamab Antineoplastic
-
XW0475 Mosunetuzumab Antineoplastic
-
XW0475 Narsoplimab Monoclonal Antibody
-
XW0476 Afamitresgene Autoleucel Immunotherapy
-
XW0476 Lefamulin Anti-infective
-
XW0476 Terlipressin
-
XW0477 Coagulation Factor Xa, Inactivated
-
XW0477 Tabelecleucel Immunotherapy
-
XW0477 Trilaciclib
-
XW0478 Lurbinectedin
-
XW0478 Mineral-based Topical Hemostatic Agent
-
XW0478 Treosulfan
-
XW0478 Uridine Triacetate
-
XW0479 Ceftolozane/Tazobactam Anti-infective
-
XW0479 Inebilizumab-cdon
-
XW0479 Satralizumab-mwge
-
XW047A Cefiderocol Anti-infective
-
XW047A Ciltacabtagene Autoleucel
-
XW047B Amivantamab Monoclonal Antibody
-
XW047B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW047B Omadacycline Anti-infective
-
XW047C Eculizumab
-
XW047C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW047D Atezolizumab Antineoplastic
-
XW047D Engineered Allogeneic Thymus Tissue
-
XW047E Etesevimab Monoclonal Antibody
-
XW047E Remdesivir Anti-infective
-
XW047F Bamlanivimab Monoclonal Antibody
-
XW047F Other New Technology Therapeutic Substance
-
XW047G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW047G Plazomicin Anti-infective
-
XW047G REGN-COV2 Monoclonal Antibody
-
XW047G Sarilumab
-
XW047H Axicabtagene Ciloleucel Immunotherapy
-
XW047H Other New Technology Monoclonal Antibody
-
XW047H Synthetic Human Angiotensin II
-
XW047H Tocilizumab
-
XW047J Apalutamide Antineoplastic
-
XW047J Tisagenlecleucel Immunotherapy
-
XW047K Fosfomycin Anti-infective
-
XW047K Idecabtagene Vicleucel Immunotherapy
-
XW047K Leronlimab Monoclonal Antibody
-
XW047L CD24Fc Immunomodulator
-
XW047L Erdafitinib Antineoplastic
-
XW047L Lifileucel Immunotherapy
-
XW047M Baricitinib
-
XW047M Brexucabtagene Autoleucel Immunotherapy
-
XW047M Esketamine Hydrochloride
-
XW047N Lisocabtagene Maraleucel Immunotherapy
-
XW047N Meropenem-vaborbactam Anti-infective
-
XW047P Antibiotic-eluting Bone Void Filler
-
XW047Q Tagraxofusp-erzs Antineoplastic
-
XW047R Fostamatinib
-
XW047R Venetoclax Antineoplastic
-
XW047S COVID-19 Vaccine Dose 1
-
XW047S Iobenguane I-131 Antineoplastic
-
XW047T COVID-19 Vaccine Dose 2
-
XW047T Ruxolitinib
-
XW047U COVID-19 Vaccine
-
XW047U Imipenem-cilastatin-relebactam Anti-infective
-
XW047V COVID-19 Vaccine Dose 3
-
XW047V Gilteritinib Antineoplastic
-
XW047W Caplacizumab
-
XW047W COVID-19 Vaccine Booster
-
XW047X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW047X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW047Y Other New Technology Monoclonal Antibody
-
-
XW048 Via Natural or Artificial Opening Endoscopic
-
XW0480 Brexanolone
-
XW0480 Spesolimab Monoclonal Antibody
-
XW0481 Daratumumab and Hyaluronidase-fihj
-
XW0481 Eladocagene exuparvovec
-
XW0482 Bromelain-enriched Proteolytic Enzyme
-
XW0482 Nerinitide
-
XW0483 Durvalumab Antineoplastic
-
XW0483 Maribavir Anti-infective
-
XW0484 Teclistamab Antineoplastic
-
XW0485 Mosunetuzumab Antineoplastic
-
XW0485 Narsoplimab Monoclonal Antibody
-
XW0486 Afamitresgene Autoleucel Immunotherapy
-
XW0486 Lefamulin Anti-infective
-
XW0486 Terlipressin
-
XW0487 Coagulation Factor Xa, Inactivated
-
XW0487 Tabelecleucel Immunotherapy
-
XW0487 Trilaciclib
-
XW0488 Lurbinectedin
-
XW0488 Mineral-based Topical Hemostatic Agent
-
XW0488 Treosulfan
-
XW0488 Uridine Triacetate
-
XW0489 Ceftolozane/Tazobactam Anti-infective
-
XW0489 Inebilizumab-cdon
-
XW0489 Satralizumab-mwge
-
XW048A Cefiderocol Anti-infective
-
XW048A Ciltacabtagene Autoleucel
-
XW048B Amivantamab Monoclonal Antibody
-
XW048B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW048B Omadacycline Anti-infective
-
XW048C Eculizumab
-
XW048C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW048D Atezolizumab Antineoplastic
-
XW048D Engineered Allogeneic Thymus Tissue
-
XW048E Etesevimab Monoclonal Antibody
-
XW048E Remdesivir Anti-infective
-
XW048F Bamlanivimab Monoclonal Antibody
-
XW048F Other New Technology Therapeutic Substance
-
XW048G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW048G Plazomicin Anti-infective
-
XW048G REGN-COV2 Monoclonal Antibody
-
XW048G Sarilumab
-
XW048H Axicabtagene Ciloleucel Immunotherapy
-
XW048H Other New Technology Monoclonal Antibody
-
XW048H Synthetic Human Angiotensin II
-
XW048H Tocilizumab
-
XW048J Apalutamide Antineoplastic
-
XW048J Tisagenlecleucel Immunotherapy
-
XW048K Fosfomycin Anti-infective
-
XW048K Idecabtagene Vicleucel Immunotherapy
-
XW048K Leronlimab Monoclonal Antibody
-
XW048L CD24Fc Immunomodulator
-
XW048L Erdafitinib Antineoplastic
-
XW048L Lifileucel Immunotherapy
-
XW048M Baricitinib
-
XW048M Brexucabtagene Autoleucel Immunotherapy
-
XW048M Esketamine Hydrochloride
-
XW048N Lisocabtagene Maraleucel Immunotherapy
-
XW048N Meropenem-vaborbactam Anti-infective
-
XW048P Antibiotic-eluting Bone Void Filler
-
XW048Q Tagraxofusp-erzs Antineoplastic
-
XW048R Fostamatinib
-
XW048R Venetoclax Antineoplastic
-
XW048S COVID-19 Vaccine Dose 1
-
XW048S Iobenguane I-131 Antineoplastic
-
XW048T COVID-19 Vaccine Dose 2
-
XW048T Ruxolitinib
-
XW048U COVID-19 Vaccine
-
XW048U Imipenem-cilastatin-relebactam Anti-infective
-
XW048V COVID-19 Vaccine Dose 3
-
XW048V Gilteritinib Antineoplastic
-
XW048W Caplacizumab
-
XW048W COVID-19 Vaccine Booster
-
XW048X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW048X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW048Y Other New Technology Monoclonal Antibody
-
-
XW04X External
-
XW04X0 Brexanolone
-
XW04X0 Spesolimab Monoclonal Antibody
-
XW04X1 Daratumumab and Hyaluronidase-fihj
-
XW04X1 Eladocagene exuparvovec
-
XW04X2 Bromelain-enriched Proteolytic Enzyme
-
XW04X2 Nerinitide
-
XW04X3 Durvalumab Antineoplastic
-
XW04X3 Maribavir Anti-infective
-
XW04X4 Teclistamab Antineoplastic
-
XW04X5 Mosunetuzumab Antineoplastic
-
XW04X5 Narsoplimab Monoclonal Antibody
-
XW04X6 Afamitresgene Autoleucel Immunotherapy
-
XW04X6 Lefamulin Anti-infective
-
XW04X6 Terlipressin
-
XW04X7 Coagulation Factor Xa, Inactivated
-
XW04X7 Tabelecleucel Immunotherapy
-
XW04X7 Trilaciclib
-
XW04X8 Lurbinectedin
-
XW04X8 Mineral-based Topical Hemostatic Agent
-
XW04X8 Treosulfan
-
XW04X8 Uridine Triacetate
-
XW04X9 Ceftolozane/Tazobactam Anti-infective
-
XW04X9 Inebilizumab-cdon
-
XW04X9 Satralizumab-mwge
-
XW04XA Cefiderocol Anti-infective
-
XW04XA Ciltacabtagene Autoleucel
-
XW04XB Amivantamab Monoclonal Antibody
-
XW04XB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW04XB Omadacycline Anti-infective
-
XW04XC Eculizumab
-
XW04XC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW04XD Atezolizumab Antineoplastic
-
XW04XD Engineered Allogeneic Thymus Tissue
-
XW04XE Etesevimab Monoclonal Antibody
-
XW04XE Remdesivir Anti-infective
-
XW04XF Bamlanivimab Monoclonal Antibody
-
XW04XF Other New Technology Therapeutic Substance
-
XW04XG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW04XG Plazomicin Anti-infective
-
XW04XG REGN-COV2 Monoclonal Antibody
-
XW04XG Sarilumab
-
XW04XH Axicabtagene Ciloleucel Immunotherapy
-
XW04XH Other New Technology Monoclonal Antibody
-
XW04XH Synthetic Human Angiotensin II
-
XW04XH Tocilizumab
-
XW04XJ Apalutamide Antineoplastic
-
XW04XJ Tisagenlecleucel Immunotherapy
-
XW04XK Fosfomycin Anti-infective
-
XW04XK Idecabtagene Vicleucel Immunotherapy
-
XW04XK Leronlimab Monoclonal Antibody
-
XW04XL CD24Fc Immunomodulator
-
XW04XL Erdafitinib Antineoplastic
-
XW04XL Lifileucel Immunotherapy
-
XW04XM Baricitinib
-
XW04XM Brexucabtagene Autoleucel Immunotherapy
-
XW04XM Esketamine Hydrochloride
-
XW04XN Lisocabtagene Maraleucel Immunotherapy
-
XW04XN Meropenem-vaborbactam Anti-infective
-
XW04XP Antibiotic-eluting Bone Void Filler
-
XW04XQ Tagraxofusp-erzs Antineoplastic
-
XW04XR Fostamatinib
-
XW04XR Venetoclax Antineoplastic
-
XW04XS COVID-19 Vaccine Dose 1
-
XW04XS Iobenguane I-131 Antineoplastic
-
XW04XT COVID-19 Vaccine Dose 2
-
XW04XT Ruxolitinib
-
XW04XU COVID-19 Vaccine
-
XW04XU Imipenem-cilastatin-relebactam Anti-infective
-
XW04XV COVID-19 Vaccine Dose 3
-
XW04XV Gilteritinib Antineoplastic
-
XW04XW Caplacizumab
-
XW04XW COVID-19 Vaccine Booster
-
XW04XX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW04XX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW04XY Other New Technology Monoclonal Antibody
-
-